Advanced search

681 Results

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Johnson & Johnson - TAR-200 monotherapy shows greater than 80% complete response rate in patients with high-risk non-muscle-invasive bladder cancer	05-06	AQ
US employment boom leaves factory workers behind	04-04	RE
Republicans hope to win Black voters for Trump. It won't be easy	04-02	RE
Zions Bancorporation N A : 2023 Annual Report Officers & Directors	03-28	PU
RELX : Notice of 2024 Annual General Meeting	03-08	PU
CORUS ENTERTAINMENT APPLAUDS ITS CREATIVE TEAMS AND PRODUCTION PARTNERS ON 65 CANADIAN SCREEN AWARDS NOMINATIONS	03-06	AQ
Johnson & Johnson - RYBREVANT in Combination with Chemotherapy Is the First FDA Approved Therapy for First-line Treatment of Patients With Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations	03-04	AQ
RYBREVANT® (amivantamab-vmjw) in Combination With Chemotherapy Is the First FDA Approved Therapy for First-line Treatment of Patients With Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations	03-01	PR
JELD-WEN Appoints Antonella Franzen to Board of Directors	02-21	PR
JELD-WEN Holding, Inc. Announces Board Changes	02-21	CI
The Trump voters in swing states who are returning to the fold	01-13	RE
The toll on migrants of a free bus north from the border	01-11	RE
Arcadium Lithium plc completed the acquisition of Allkem Limited (ASX : AKE) in a merger of equals transaction.	01-03	CI
Johnson & Johnson Submits Supplemental Biologics License Application and New Drug Application to U.S. FDA Seeking Approval of RYBREVANT Plus Lazertinib for the Treatment of Patients with EGFR-Mutated Non-Small Cell Lung Cancer	12-22	AQ
Voter advocates, conservative activists brace for 2024 election showdowns	12-07	RE
Johnson & Johnson's Investigational TAR-200 Granted U.S. FDA Breakthrough Therapy Designation for the Treatment of High-Risk Non-Muscle-Invasive Bladder Cancer	12-05	AQ
Asset manager GMO's first ETF will focus on 'quality' companies	11-13	RE
Johnson & Johnson : Phase 3 MARIPOSA-2 Study Shows RYBREVANT® (amivantamab-vmjw) Plus Chemotherapy Given with or without Lazertinib Reduced Risk of Disease Progression or Death by 56% and 52% in Patients with EGFR-Mutated NSCLC who Progressed on or after Osimertinib	23-10-23	PU
Johnson & Johnson : Landmark Phase 3 MARIPOSA Study Shows RYBREVANT® (amivantamab-vmjw) Plus Lazertinib Resulted in 30 Percent Reduction in Risk of Disease Progression or Death Compared to Osimertinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer	23-10-23	PU
Janssen Pharmaceutical - Final Multivariate Analysis from the Phase 3 MAGNITUDE Study Shows Trend toward Improvement in OS in Patients with mCRPC with BRCA Alterations Treated with Niraparib and Abiraterone Acetate plus Prednisone	23-10-23	AQ
Janssen Pharmaceutical - First Results with Erdafitinib-Releasing Intravesical Delivery System Show Early Evidence of Positive Clinical Activity in Patients with Non-Muscle-Invasive Bladder Cancer with Select FGFR Alterations	23-10-23	AQ
Janssen Pharmaceutical - Results from Phase 2 THOR-2 Study Show Improved Rates of Recurrence-Free Survival in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer	23-10-23	AQ
Janssen Pharmaceutical - TAR-200 Intravesical Delivery System Results Show 77 Percent Complete Response Rate in Patients with Bacillus-Calmette-Guerin Unresponsive, High-Risk Non-Muscle-Invasive Bladder Cancer	23-10-23	AQ
Janssen Pharmaceutical - First Results with Erdafitinib-Releasing Intravesical Delivery System Show Early Evidence of Positive Clinical Activity in Patients with Non-MuscleInvasive Bladder Cancer with Select Fibroblast Growth Factor Receptor Alterations	23-10-23	AQ
Johnson & Johnson : New Data from Phase 3 PAPILLON Study Show RYBREVANT® (amivantamab-vmjw) Plus Chemotherapy Resulted in 60% Reduction in Risk of Disease Progression or Death in Patients with Previously Untreated EGFR Exon 20 Insertion Mutation-Positive NSCLC	23-10-23	PU
Johnson & Johnson : Results from Phase 2 THOR-2 Study Show Improved Rates of Recurrence-Free Survival in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer with Select Fibroblast Growth Factor	23-10-23	PU
Johnson & Johnson : New Data from Phase 3 PAPILLON Study Show RYBREVANT® (amivantamab-vmjw) Plus Chemotherapy Resulted in 60% Reduction in Risk of Disease Progression or Death in Patients with Previously Untreated EGFR Exon 20 Insertion Mutation-Positive NSCLC	23-10-20	PU
Johnson & Johnson : Results from Phase 2 THOR-2 Study Show Improved Rates of Recurrence-Free Survival in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer with Select Fibroblast Growth Factor	23-10-20	PU
Johnson & Johnson : Janssen Aims to Define New Standards of Care in the Treatment of Solid Tumor Cancers with Transformative Data Planned for Presentation at ESMO	23-10-16	PU
Transcript : Accuray Incorporated - Analyst/Investor Day	23-10-03
Johnson & Johnson : Landmark Phase 3 MARIPOSA Study Meets Primary Endpoint Resulting in Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival for RYBREVANT® (amivantamab-vmjw) plus Lazertinib Versus Osimertinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer	23-09-27	PU
Janssen Pharmaceutical - Treatment with RYBREVANT and Lazertinib Plus Chemotherapy Showed Durable Progression-Free Survival in Patients with Previously Treated EGFR-Mutated Advanced Non-Small Cell Lung Cancer	23-09-12	AQ
Salesforce Gives $20M to Education, Expanding Pathways into Tech and AI Careers	23-09-11	BU
Janssen - Phase 3 MARIPOSA-2 Study Meets Dual Primary Endpoint Resulting in Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival for RYBREVANT plus Chemotherapy	23-09-07	AQ
Johnson & Johnson : Janssen Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of BALVERSA® (erdafitinib) for the Treatment of Patients with Locally Advanced or Metastatic Urothelial Carcinoma and Selected Fibroblast Growth Factor Receptor Gene Alterations	23-08-30	PU
Johnson & Johnson : Janssen Submits Supplemental Biologics License Application to the U.S. Food and Drug Administration Seeking Approval of RYBREVANT® (amivantamab-vmjw) in Combination with Chemotherapy for the First-line Treatment of Patients with Locally Advanced or Metastatic EGFR Exon 20 Insertion Mutation-Positive Non Small Cell Lung Cancer	23-08-24	PU
The Cigna Group Foundation and YMCA Partner To Improve Community Vitality in Five Cities	23-08-16	PR
Transcript : Nanobiotix S.A. - Special Call	23-07-10
Perspective Therapeutics to Present at the 2023 Annual Society for Nuclear Medicine and Molecular Imaging Conference	23-06-08	GL
Perspective Therapeutics to Present at the 2023 Annual Society for Nuclear Medicine and Molecular Imaging Conference	23-06-08	AQ
Janssen Pharmaceutical - New Long-Term Data from the CHRYSALIS Study Show Median Progression-Free Survival Not Reached after 33.6 Months of Follow-Up with First-Line Use of RYBREVANT and Lazertinib Combination Therapy	23-06-05	AQ
McCarthy's moment: Debt ceiling vote secures Republican US House speaker's standing	23-06-01	RE
SEALED AIR CORP/DE : Submission of Matters to a Vote of Security Holders (form 8-K)	23-05-22	AQ
Livent Corporation signed a definitive agreement to acquire Allkem Limited in a merger of equals transaction for $6.4 billion.	23-05-09	CI
Janssen Reports First Results from Phase 2 SunRISe-1 Study of TAR-200 and Anti- PD-1 Antibody Cetrelimab in Patients with Bacillus Calmette-Guerin-Unresponsive Non-Muscle-Invasive Bladder Cancer	23-05-01	AQ
PFIZER INC : Submission of Matters to a Vote of Security Holders (form 8-K)	23-05-01	AQ
Transcript : NRx Pharmaceuticals, Inc., Q4 2022 Earnings Call, Mar 30, 2023	23-03-30
ReFrame and IMDbPro Announce 2022 ReFrame Stamp Film Recipients	23-03-01	BU
RELX : Governance 23 February 2023	23-02-23	PU
Before facing Trump in 2024, DeSantis seeks wins on guns, abortion	23-02-10	RE

No results for this search

-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.

BENEFIT NOW